TG Therapeutics posts Q2 2026 results, raises BRIUMVI revenue guidance
The company raised its full-year 2026 revenue targets and reported positive Phase 3 data supporting a simplified BRIUMVI dosing regimen.
TG Therapeutics reported financial results for the second quarter of 2026 on August 3, 2026, alongside several pipeline updates. The company said BRIUMVI U.S. net product revenue reached $227.7 million for the second quarter, an approximately 64% increase over the same period last year, with total global revenue of $240.3 million.1
On the subcutaneous BRIUMVI program, TG Therapeutics announced positive pharmacokinetic, pharmacodynamic, safety, and tolerability data from a Phase 1 trial comparing the subcutaneous formulation of ublituximab to IV BRIUMVI, with the subcutaneous version showing mean bioavailability of greater than 60% relative to IV administration.1 The company said PK modeling based on that data supports the quarterly subcutaneous dosing regimen now being tested in a fully enrolled Phase 3 trial, with top-line data expected by year-end 2026 or early 2027.1
The company also reported positive topline results from its Phase 3 "ENHANCE" trial. According to the release, the trial met its primary endpoint, showing bioequivalent drug exposure between the currently approved BRIUMVI initiation regimen (150 mg on Day 1 and 450 mg on Day 15) and a consolidated single 600 mg infusion on Day 1, which would remove the need for the Day 15 infusion.1
In myasthenia gravis, TG Therapeutics reported positive topline Phase 1 data for subcutaneous BRIUMVI and initiated a potentially registration-directed randomized Phase 2 trial evaluating IV BRIUMVI as maintenance therapy following induction with efgartigimod.1 The company also initiated a Phase 2 trial evaluating BRIUMVI in adults with treatment-resistant schizophrenia.1
TG Therapeutics raised its full-year 2026 target for total global revenue to approximately $950 million and its BRIUMVI U.S. net product revenue target to $890 million to $905 million.1 As of quarter-end, cash, cash equivalents and investment securities were $612.3 million, which the company said, combined with projected BRIUMVI revenues, would be sufficient to fund its business under its current operating plan.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.